ATE335512T1 - Verminderungsregulation der genexpression durch kolorektale verabreichung von synthetischen oligonukleotiden - Google Patents

Verminderungsregulation der genexpression durch kolorektale verabreichung von synthetischen oligonukleotiden

Info

Publication number: ATE335512T1
Authority: AT; Austria
Prior art keywords: gene expression; synthetic oligonucleotides; administration; reduced regulation; colorectal
Prior art date: 1997-03-12

Application number

AT98911615T

Other languages

English (en)

Inventor

Ruiwen Zhang

Sudhir Agrawal

Original Assignee

Idera Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-03-12

Filing date

1998-03-12

Publication date

2006-09-15

1998-03-12 Application filed by Idera Pharmaceuticals Inc filed Critical Idera Pharmaceuticals Inc

2006-09-15 Application granted granted Critical

2006-09-15 Publication of ATE335512T1 publication Critical patent/ATE335512T1/de

Links

108091034117 Oligonucleotide Proteins 0.000 title abstract 4
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
230000014493 regulation of gene expression Effects 0.000 title 1
241000124008 Mammalia Species 0.000 abstract 2
241001465754 Metazoa Species 0.000 abstract 2
108090000623 proteins and genes Proteins 0.000 abstract 2
230000000295 complement effect Effects 0.000 abstract 1
230000002222 downregulating effect Effects 0.000 abstract 1
230000009885 systemic effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Virology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Oncology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
Pulmonology (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT98911615T 1997-03-12 1998-03-12 Verminderungsregulation der genexpression durch kolorektale verabreichung von synthetischen oligonukleotiden ATE335512T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US4073897P	1997-03-12	1997-03-12
US84641797A	1997-04-30	1997-04-30

Publications (1)

Publication Number	Publication Date
ATE335512T1 true ATE335512T1 (de)	2006-09-15

Family

ID=26717368

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT98911615T ATE335512T1 (de)	1997-03-12	1998-03-12	Verminderungsregulation der genexpression durch kolorektale verabreichung von synthetischen oligonukleotiden

Country Status (7)

Country	Link
EP (1)	EP1007098B1 (de)
JP (1)	JP2001527536A (de)
AT (1)	ATE335512T1 (de)
AU (1)	AU6553398A (de)
CA (1)	CA2283684C (de)
DE (1)	DE69835525T2 (de)
WO (1)	WO1998040058A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1999009154A2 (en)	1997-08-19	1999-02-25	Hybridon, Inc.	Novel hiv-specific synthetic oligonucleotides and methods of their use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU6165494A (en) *	1993-01-25	1994-08-15	Hybridon, Inc.	Oligonucleotide alkylphosphonates and alkylphosphonothioates
US6348449B1 (en) *	1993-09-21	2002-02-19	The Trustees Of The University Of Pennsylvania	Methods of inducing mucosal immunity
US5591721A (en) *	1994-10-25	1997-01-07	Hybridon, Inc.	Method of down-regulating gene expression
AU6505796A (en) *	1995-07-26	1997-02-26	Maxim Pharmaceuticals	Mucosal delivery of polynucleotides

1998
- 1998-03-12 AT AT98911615T patent/ATE335512T1/de not_active IP Right Cessation
- 1998-03-12 EP EP98911615A patent/EP1007098B1/de not_active Expired - Lifetime
- 1998-03-12 DE DE69835525T patent/DE69835525T2/de not_active Expired - Lifetime
- 1998-03-12 CA CA2283684A patent/CA2283684C/en not_active Expired - Fee Related
- 1998-03-12 WO PCT/US1998/004914 patent/WO1998040058A2/en not_active Ceased
- 1998-03-12 JP JP53982398A patent/JP2001527536A/ja active Pending
- 1998-03-12 AU AU65533/98A patent/AU6553398A/en not_active Abandoned

Also Published As

Publication number	Publication date
JP2001527536A (ja)	2001-12-25
DE69835525T2 (de)	2007-03-08
CA2283684C (en)	2010-06-08
DE69835525D1 (de)	2006-09-21
EP1007098B1 (de)	2006-08-09
CA2283684A1 (en)	1998-09-17
AU6553398A (en)	1998-09-29
EP1007098A2 (de)	2000-06-14
WO1998040058A2 (en)	1998-09-17
WO1998040058A3 (en)	1998-11-19

Similar Documents

Publication	Publication Date	Title
ATE288480T1 (de)	2005-02-15	Chondrogene in vitro induktion von menschlichen mensenchymalen stammzellen
AU1926899A (en)	1999-07-12	Exploiting genomics in the search for new drugs
DE69637726D1 (de)	2008-12-04	Gruppen zum einfangen von nukleinsäuren
Hilwig et al.	1975	pH-dependent fluorescence of DNA and RNA in cytologic staining with “33258 Hoechst”
UA74339C2 (uk)	2005-12-15	Форма для введення, що включає інгібітор протонної помпи у вигляді окремих одиниць, та спосіб їх одержання
ATE345682T1 (de)	2006-12-15	In vitro verfahren zum einbringen von nukleinsäuren in eine zelle
FR2686657B1 (fr)	1994-08-12	Pompe motorisee, notamment pour carburant.
EA199700155A1 (ru)	1997-12-30	Ингибиторы тромбина
BG98106A (en)	1994-07-15	Dendrite macromolecule and method for its preparation
TR199900262T2 (xx)	1999-03-22	Drospirenon (6�, 7�; 15�, 16�-dimetilen-3-okso-17 alfa-pregn-4-ene-21, 17-karbolakton, DRSP) ve y�ntemin ara �r�nleri olarak 7alfa-(3-hidroksi-1-propil)-6�, 7�;15�, 16�-dimetilen-5�-androstan-3�, 5, 17B-triol (ZK92836) ve 6�, 7�;15�, 16�-dimetilen - 5� -hidroksi-3-okso-17alfa-androstan-21,17-karbolaktonun (90965) �retilmeleri i�in y�ntem.
DK0948255T3 (da)	2006-03-06	Forbedret chondrogen differentiering af humane mesenkymale stamceller
DK1448229T3 (da)	2010-03-08	Farmaceutisk sammensætning til at inducere et immunrespons hos et menneske eller et dyr
EE03955B1 (et)	2003-02-17	Nukleiinhappe kasutamine ravimi valmistamiseks imetaja reproduktiivtrakti vähemalt mõne raku transfekteerimiseks
ATE258923T1 (de)	2004-02-15	Amphiphile imidazolinium-derivate
Coleman et al.	1965	Extracellular ribonuclease formation in Bacillus subtilis and its stimulation by actinomycin D
WO1992020796A3 (en)	1993-03-04	D-type cyclin and uses related thereto
AR012853A1 (es)	2000-11-22	Formulacion inyectable transparente de compuesto anestesico
HU9800329D0 (en)	1998-04-28	Nucleic acid construct for the cell cycle regulated expression of structural genes
GEP20063972B (en)	2006-11-27	Streptogramin derivatives, preparation and compositions containing them
TWI255720B (en)	2006-06-01	Novel preparation and administration form comprising an acid-labile active compound and process for production thereof
Covelli et al.	1972	The mechanism of action of the epidermal growth factor: III. Stimulation of the uptake of labeled precursors into RNA, DNA and proteins induced by EGF in isolated tumor cells
ATE240390T1 (de)	2003-05-15	Verfahren des transfers von genen in aktivierten zellen ausgehend von einem zustand des teilungsstillstandes
AU1060397A (en)	1997-06-19	High efficiency tissue specific compound delivery system using streptavidin-protein a fusion protein
DE69835525D1 (de)	2006-09-21	Verminderungsregulation der genexpression durch kolorektale verabreichung von synthetischen oligonukleotiden
ID26346A (id)	2000-12-14	PROSES PEMBUATAN TURUNAN ASAM 5-HIDROKSIBENZO (b)TIOFEN-3-KARBOKSILAT

Legal Events

Date	Code	Title	Description
2007-02-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties